PHARMACEUTICAL

Pioneering the use of milk exosomes as an innovative drug delivery platform

BENEFITS

Uniquely powerful properties of
milk-derived exosomes (mEVs)

These nanoscale vesicles, naturally found in milk, act as inherent messengers within the body, offering an exceptional and biocompatible platform for transporting therapeutic cargoes.

Can be orally administered with high bioavailability.

Bypasses the gut-blood, vascular & blood-brain barriers, penetrating tissues and cells.

Directly homes to the site of the injury or inflammation.

Delivers cargoes into cells to activate the development or healing process.

Naturally stable, capable of long-term shelf stability.

Non-immunogenic, consumed by billions daily.

“Milk exosomes contain the potential to stand as a new modality of drug delivery — with an all-natural packaging system, Tiny Cargo is poised to revolutionize therapeutics.”

Spencer Marsh

Chief Scientific Officer
The Tiny Cargo Company

SERVICES

Platform-based
drug-loading

We provide pharmaceutical companies with access to our high-efficiency, functionality-preserving loading technology to enhance the delivery of their own therapeutic candidates.

Our expert team can collaborate with you to optimize exosome loading and accelerate your drug development pipeline.

A broad spectrum of cargoes

Tiny Cargo’s platform-based loading approach is versatile, capable of loading a wide range of therapies, weights and sizes.

Small molecules

To date, >95% loading efficiency has been achieved for a variety of small molecules 

Monoclonal Antibodies

To date, 60% loading efficiency has been achieved for mAbs; further loading optimisation is in progress

Biologics

>90% loading efficiency with biologics, including monoclonal antibodies (mAbs) up to 150 kDa achieved to date.

mRNA

Loading studies in progress

Antisense oligonucleotides

Loading studies in progress

Peptides

>99% loading efficiency achieved for peptide therapeutics to date, including the modified αCT11 peptide in our proprietary drug, XOlacta.

GLP-1 Receptor Agonists

Loading studies in progress

Latest publications

Keen to learn more?